Gene: CLSTN2

64084
ALC-GAMMA|CDHR13|CS2|CSTN2|alcagamma
calsyntenin 2
protein-coding
3q23
Ensembl:ENSG00000158258 MIM:611323 Vega:OTTHUMG00000160139 UniprotKB:Q9H4D0
NC_000003.12
SNP Mapped
5   ANCO-SNPs
ND|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.227e-1 (AD)  6.532e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6439914chr3:140290378 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs4077501chr3:140278306 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs7626587chr3:140274852 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs6798469chr3:140182692 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs16849613chr3:139979746 (GRCh38.p7)T>Anicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ERC20.939
PTPRT0.934
RYR20.928
NELL10.921
DIRAS20.921
CPNE40.919
RASGRP10.918
CNIH30.917
FAM102B0.914
PDE1A0.912

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASB4-0.593
RAB13-0.58
RNF135-0.561
COPZ2-0.558
LRAT-0.556
YES1-0.553
CHST14-0.542
PON3-0.541
S100A16-0.539
HEY2-0.538

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of CLSTN2 mRNA"19114083
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of CLSTN2 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CLSTN2 gene27153756
D001280AtrazineAtrazine results in decreased expression of CLSTN2 mRNA25929836
C030935benz(a)anthracene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA27858113
C006703benzo(b)fluoranthene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA27858113
D001564Benzo(a)pyrene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA27858113
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of CLSTN2 mRNA21839799
D004958EstradiolEstradiol results in decreased expression of CLSTN2 mRNA20068009
D004958EstradiolEstradiol results in increased expression of CLSTN2 mRNA17010207
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA28628672
C006780bisphenol Abisphenol A results in decreased expression of CLSTN2 mRNA25181051
D002509CephaloridineCephaloridine results in decreased expression of CLSTN2 mRNA18500788
C031180chrysene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA27858113
D003471CuprizoneCuprizone results in decreased expression of CLSTN2 mRNA26577399
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA28628672
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of CLSTN2 mRNA17010207
D004397FonofosFonofos results in increased methylation of CLSTN2 promoter22847954
D005557FormaldehydeFormaldehyde results in increased expression of CLSTN2 mRNA28937961
C412815GW 4064GW 4064 results in decreased expression of CLSTN2 mRNA26655953
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA28628672
D007854LeadLead affects the expression of CLSTN2 mRNA28903495
D008070LipopolysaccharidesLipopolysaccharides results in decreased methylation of CLSTN2 gene21212295
D008070Lipopolysaccharides[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLSTN2 gene21212295
C002950methylformamidemethylformamide analog results in increased expression of CLSTN2 mRNA17040096
C002950methylformamidemethylformamide results in increased expression of CLSTN2 mRNA17040096
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of CLSTN2 mRNA28001369
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of CLSTN2 mRNA24810058
C500085muraglitazarmuraglitazar results in decreased expression of CLSTN2 mRNA21515302
D009532NickelNickel results in decreased expression of CLSTN2 mRNA25583101
C474055octylphenoloctylphenol results in increased expression of CLSTN2 mRNA17010207
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of CLSTN2 mRNA26272509
D010278ParathionParathion results in increased methylation of CLSTN2 promoter22847954
D052638Particulate MatterParticulate Matter results in decreased expression of CLSTN2 mRNA23085030
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in increased expression of CLSTN2 mRNA26705709
D010634PhenobarbitalPhenobarbital affects the methylation of CLSTN2 gene19233941
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C006253pirinixic acidpirinixic acid results in decreased expression of CLSTN2 mRNA20813756
D011374ProgesteroneProgesterone results in increased expression of CLSTN2 mRNA22238285
D011374ProgesteroneProgesterone results in increased expression of CLSTN2 mRNA20726854
D011441PropylthiouracilPropylthiouracil results in decreased expression of CLSTN2 mRNA24780913
C089730rosiglitazonerosiglitazone results in decreased expression of CLSTN2 mRNA21515302
C017947sodium arsenitesodium arsenite affects the methylation of CLSTN2 gene28589171
C012568terbufosterbufos results in increased methylation of CLSTN2 promoter22847954
C501413tesaglitazartesaglitazar results in decreased expression of CLSTN2 mRNA21515302
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLSTN2 gene21212295
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased methylation of CLSTN2 gene21212295
C009495titanium dioxidetitanium dioxide affects the expression of CLSTN2 mRNA23557971
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of CLSTN2 mRNA26272509
C057693troglitazonetroglitazone results in decreased expression of CLSTN2 mRNA21515302
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of CLSTN2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of CLSTN2 mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of CLSTN2 gene25560391
D000069470Venlafaxine HydrochlorideVenlafaxine Hydrochloride results in decreased expression of CLSTN2 mRNA25423262
C025643vinclozolinvinclozolin affects the expression of CLSTN2 mRNA19015723

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005509calcium ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007156homophilic cell adhesion via plasma membrane adhesion molecules-IEA-  
GO:0050806positive regulation of synaptic transmission-IBA21873635  
GO:0050806positive regulation of synaptic transmission-IEA-  
GO:0051965positive regulation of synapse assembly-IBA21873635  
GO:0051965positive regulation of synapse assembly-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IEA-  
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0009986cell surface-IBA21873635  
GO:0009986cell surface-IEA-  
GO:0014069postsynaptic density-IEA-  
GO:0016021integral component of membrane-IEA-  
GO:0045211postsynaptic membrane-IBA21873635  
GO:0045211postsynaptic membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal